Sprint Bioscience AB (publ) (SPRINT)
Free
No email, no account, no signup.
Pulling latest news for Sprint Bioscience AB (publ)…
Bull
Bear
Professional stock analysis at introductory pricing. 7-day money-back guarantee — no lock-in.
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99 $1.25.
Get the deep 4-model report – Signal
NEUTRAL
Sentiment
7/10
Risk
7/10
Get full analysis with Bull/Bear case, catalysts, and risk analysis
Buy express analysis –
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Sentiment is described as broadly **positive** after the Gilead deal, focusing on perceived undervaluation, future milestones, and new partnering. Social chatter appears relatively limited and news-driven.
Exchange
Nasdaq First North Premier Growth Market
Type
Biotech
Sector
Biotech (preclinical oncology drug development)
Market Cap
$25M
Market sentiment
Sentiment is described as broadly **positive** after the Gilead deal, focusing on perceived undervaluation, future milestones, and new partnering. Social chatter appears relatively limited and news-driven.
Why NEUTRAL ?
- **REVIEW** due to mixed inputs: strong validation via the Gilead deal, but still high preclinical risk.
- Cash figures differ across sources; the next report is important to confirm cash and burn.
- Upside is option-like via new deals/milestones, but timing/probability is uncertain.
- Hold/watch; consider adding only after confirmed new deals or milestones.
Recent News
- Since 2026-06-19, no new material press releases or company-specific events have been identified. The latest known flow remains: Q1 2026 (May) with net sales 0 MSEK, EBIT −14.3 MSEK and cash 108.3 MSEK; positive preclinical PoC data in the VRK1 program; updated scientific evidence for DCPS (AACR) and expansion of the NNMT track; and participation in partnering/investor activities in June. The next clear datapoint is the Q2 report on 26 August 2026.
Bull case
- **Momentum** and higher visibility after the **Gilead** TREX1 deal
- Upcoming report may confirm improved cash/burn after the upfront
- Preclinical data points (e.g., DCPS/NNMT) can support interest
Unlock to read more →
Bear case
- Limited near-term news flow can trigger a **pullback** after deal-driven strength
- **Low liquidity** can amplify volatility
- Market may discount milestones as distant and uncertain
Unlock to read more →
Catalysts
26 Aug 2026 — Q2 / Half-year report 2026 (Jan–Jun)
Dilution Risk
Assessment: Medium
Order analysis – $4.99 $1.25
Save hours of research. $4.99 $1.25.
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Want to read the full analysis?
Order a fresh analysis of Sprint Bioscience AB (publ) – ready in your inbox in 5–15 minutes.
- Signal + risk + sentiment
- Bull/Bear case + triggers
- Catalysts with dates
- Saved as a webpage in your account
- Ready in 5–15 min (email when ready)
Full analysis at introductory pricing — 7-day money-back guarantee.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Fact-based analysis
Updated weekly
No commitment period
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.